Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

FDA Guidance on Biosimilar Naming to Support Pharmacovigilance

XTALKS VITALS NEWS

Biosimilar

The regulator will require the addition of a four-letter, non-word suffix to the name of the drug’s active ingredient in order to differentiate between the biopharma products, and facilitate pharmacovigilance efforts.

Share this!

January 16, 2017 | by Sarah Hand, M.Sc.

After much speculation and debate, the US Food and Drug Administration (FDA) has released guidance for biologic and biosimilar product naming conventions. The regulator will require the addition of a four-letter, non-word suffix to the name of the drug’s active ingredient in order to differentiate between the biopharma products, and facilitate pharmacovigilance efforts.

Unlike generic drugs, biosimilars are not chemically-identical to their reference biologic, and therefore cannot be freely substituted. The new suffix rule was designed to help prevent pharmacists from inadvertently dispensing a biosimilar in place of the branded biologic.

As the FDA has so-far only approved four biosimilar drugs – Zarxio, Inflectra, Erelzi and Amjevita – it has already applied the naming convention of adding the four-letter suffix to the non-proprietary name of these products. For example, the non-proprietary name of Sandoz’ Zarxio is filgrastim-sndz. However, the FDA’s finalized guidance will require biologics makers to add a unique suffix to their drug products as well.



When the rule was still in review, pharmaceutical trade organizations including PhRMA and BIO urged the FDA to make the four-letter additions meaningful. They argued that suffixes based on the sponsor company’s name would be easier to remember, therefore potentially improving pharmacovigilance.

“PhRMA believes that adopting meaningful suffixes that are generally derived from that name of the sponsor or application holder will enhance prescriber recognition, use, and memory of suffixes and thus, the utility of suffixes for their pharmacovigilance and safety objectives,” PhRMA said in a comment to the FDA. “Suffixes that are “devoid of meaning” likely will prove difficult to remember and, as a result, are less likely to be used consistently throughout the healthcare delivery system.”

Unfortunately, PhRMA didn’t get their request, however the FDA plans on helping the industry by assigning suffixes to a selection of approved biologics. The agency is also working on implementing a process to encourage biopharma companies to adopt the naming convention.

These four-letter additions should help distinguish biologic and biosimilar drugs, and help pharmacovigilance teams track adverse events. As the number of biologics going off-patent continues to increase, the biosimilars market is expected to expand in the next few years.


Keywords: FDA, Biosimilar, Pharmacovigilance


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
New Approach Could Allow Red Blood Cells to be Manufactured

March 27, 2017 - UK researchers at the University of Bristol have developed an immortal line of early adult erythroblasts capable of continuously producing mature red blood cells.

Featured In: Biotech News


Lung Cancer Recurrence Could Be Better Detected Using Biomarker Blood Test

March 24, 2017 - The results of a recent prospective clinical trial found that a biomarker blood test could detect lung cancer recurrence a full six months before imaging methods could spot the disease.

Featured In: Biotech News


Use of Testosterone Treatments Boosted by DTC Ad Campaigns

March 24, 2017 - Those with a stake in the pharmaceutical industry often question the effectiveness of direct-to-consumer (DTC) advertising, and whether it truly influences consumers to talk to their doctors about medical conditions and perhaps even ask for drugs by name.

Featured In: Pharmaceutical Marketing News

LEAVE A COMMENT
 
  
THE XTALKS VITALS LIFE SCIENCE BLOG

Will Pharmaceutical Serialization Solve All of Our Drug Counterfeiting Problems?

REGISTER FOR THESE WEBINARS

How to Improve the Speed and Efficiency of Your Clinical Trials


High Performance Computing for High Content Screening - A Case Study


The FDA Guidance on the Assessment of Abuse Potential of Drug – A Critical Review


Treatment of Psoriasis: Improvements Through Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.